Cytek Biosciences Inc (CTKB)
Quick ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 98,716 | 167,299 | 296,601 | 364,618 | 165,231 |
| Short-term investments | US$ in thousands | 179,145 | 95,111 | 44,548 | 0 | — |
| Receivables | US$ in thousands | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 67,663 | 56,226 | 49,040 | 32,160 | 26,536 |
| Quick ratio | 4.11 | 4.67 | 6.96 | 11.34 | 6.23 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($98,716K
+ $179,145K
+ $—K)
÷ $67,663K
= 4.11
The quick ratio of Cytek Biosciences Inc has shown varying trends over the five-year period from December 31, 2020, to December 31, 2024. The quick ratio, which measures the company's ability to meet short-term obligations with its most liquid assets, increased significantly from 6.23 in 2020 to 11.34 in 2021, indicating a strong liquidity position.
However, the ratio declined in the following years, reaching 4.11 by December 31, 2024. A quick ratio above 1 indicates that the company has enough liquid assets to cover its short-term liabilities. Despite the decrease in the quick ratio over the years, Cytek Biosciences Inc still maintains a healthy level of liquidity overall, as its quick ratio remains above 1 in each year, suggesting a relatively low risk of financial distress due to liquidity issues.
While the quick ratio has fluctuated, it is important for the company to closely monitor its liquidity position to ensure it can continue to meet its short-term obligations efficiently and navigate any potential challenges that may arise in the future.
Peer comparison
Dec 31, 2024